CCR6 antagonist 1

Research use only, not for human use.

CCR6 antagonist 1, a chemical compound acting as a CCR6 antagonist, effectively inhibits the CCL20/CCR6 axis. Its utility lies in research focused on autoimmune-mediated inflammatory diseases, including inflammatory bowel diseases (IBDs).

CCR6 antagonist 1 is a CCR6 antagonist that inhibits the CCL20/CCR6 axis. CCR6 antagonist 1 can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs).

Cell Migration Assay Cell Line:CCL20 (500 ng/mL)-induced CCR6+CD4+ T cell Concentration:0.5, 5, 50 μM Incubation Time:3 h Result:Inhibited CCL20-induced cell migration at 50 μM.

Animal Model:Murine model of colitis (5 mg/mouse TNBS-induced)Dosage:1 mg/kg Administration:Subcutaneous injection (s.c.), twice daily for 3 days. Result:Improved mice general conditions, attenuated macroscopic injury and counteracted neutrophils infiltration, both in the colon and in lungs.Animal Model:Zymosan-induced peritonitis mice Dosage:1 mg/kg Administration:Subcutaneous injection (s.c.), twice, before and after zymosan treatment Result:Significantly reduced the total protein content and myeloperoxidase activity in the peritoneal lavage.

——

Autophagy

CCR

CCR

——

——

588674-64-0

319.28

C17H12F3NO2

>98% (HPLC)

In Vitro:?DMSO : ≥ 100 mg/mL (313.20 mM )

Cc1c(oc2ccccc12)C(=O)Nc1ccc(cc1)C(F)(F)F

——

(-20℃)

With Ice Pack

≥ 2 years